Therapeutic abortion and Chlamydia trachomatis infection

ERIK QVIGSTAD,* KJELL SKAUG,† FRIDTJOF JERVE,* INGER S S VIK,† AND JAN C ULSTRUP†

From the *Department of Obstetrics and Gynaecology, and the †Microbiological Laboratory, Ullevaal Hospital, Oslo, Norway

SUMMARY Chlamydia trachomatis was isolated from the cervix of 30 of 218 (13·8%) women admitted for legal termination of pregnancy. During the first two weeks after the abortion seven of the 30 (23·3%) patients developed pelvic inflammatory disease. Four of these had serological evidence of recent active chlamydial infection. Thus, routine examination of patients for genital chlamydial infection before termination of pregnancy is recommended.

Introduction

The presence of Chlamydia trachomatis in the cervix is a frequent causal factor in the epidemiology of pelvic inflammatory disease (PID).1-4 One episode of PID may result in tubal dysfunction; tubal patency is rapidly impaired by recurrent infections and may later cause infertility.5 PID due to C trachomatis may also occur without subjective symptoms.3

PID is a major complication after therapeutic abortion; the readmission rate in our hospital is about 4%, pelvic infections and retained products being the main causes.6

The aim of this study was to record the incidence of C trachomatis infections among patients admitted for legal abortion and to follow those harbouring chlamydia, particularly those in whom it caused post-operative infections.

Patients and methods

STUDY POPULATION

Two hundred and eighteen women admitted consecutively for termination of pregnancy in the first trimester in 1980 were included in the study. Abortion was carried out by dilatation and vacuum aspiration in all patients.

The diagnosis of PID was made on the clinical grounds of pelvic pain, adnexal masses, increased erythrocyte sedimentation rate, and fever. The patients who developed acute salpingitis were treated with doxycycline.

Patients who harbourred C trachomatis were recalled for follow up about three months after the abortion.

Address for reprints: Dr E Qvigstad, Department of Obstetrics and Gynaecology, Ullevaal Hospital, Oslo 1, Norway

Accepted for publication 19 November 1981

ISOLATION OF C TRACHOMATIS AND N GONORRHOEAE

Before surgery specimens for culture of C trachomatis and N gonorrhoeae were obtained from the cervix and cultured within 24 hours. The chlamydial specimens were collected with cotton-tipped swabs and transported in a sucrose phosphate buffer (2SP). C trachomatis was cultured in cycloheximide-treated McCoy cells.7

Specimens for culture of N gonorrhoeae were collected with charcoal-treated cotton-tipped swabs and transported in a modified Stuart medium. N gonorrhoeae was cultured on a modified Thayer-Martin medium and identified by sugar fermentation tests.

SEROLOGY

Before abortion and at follow-up examination serum samples were examined for chlamydial IgG antibodies by an enzyme-linked immunosorbent assay (ELISA).8 The ELISA was performed on flat-bottomed microtitre plates coated with a suspension of partially purified cell-cultured C trachomatis sub-type LGV-2 particles. Antibody titres were expressed as the highest reciprocal serum dilution showing at least twice the mean absorbance value of a group of negative sera. A titre >1/8 was defined as a positive result. A four-fold or more rise in titre was regarded as evidence of actual chlamydial infection.

Results

CULTURE

Of the 218 patients, C trachomatis was isolated from the cervix in 30 (13·8%), N gonorrhoeae in six (2·8%), and both C trachomatis and N gonorrhoeae in two.
**Therapeutic abortion and Chlamydia trachomatis infection**

Seven of the 30 (23·3%) patients harboring *C. trachomatis* developed PID. All the infections occurred in the first two weeks after the abortion. None of the patients with cervical gonorrhoea developed salpingitis.

**FOLLOW UP**

Twenty-one of the 30 chlamydia-positive patients attended for follow up three months after the termination of pregnancy (table). Of the seven patients with pelvic infection, six attended (patients 1-6); four of these had an appreciable rise in chlamydia IgG antibody titre while two had raised but unchanged titres. A further four patients (Nos 7-10) had a four-fold or more rise in titre but no clinical evidence of infection.

**Table Chlamydial IgG antibody titres in paired serum samples from 21 patients harbouring *C. trachomatis* by an enzyme-linked immunosorbent assay before abortion and at follow up**

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Serum IgG antibody titres</th>
<th>First sample*</th>
<th>Second sample†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>32</td>
<td>128</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>8</td>
<td>32</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>8</td>
<td>32</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>128</td>
<td>512</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>&lt;8</td>
<td>2048</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>8</td>
<td>512</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>32</td>
<td>512</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>32</td>
<td>256</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td>&lt;8</td>
<td>&lt;8</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td>&lt;8</td>
<td>&lt;8</td>
</tr>
<tr>
<td>16</td>
<td></td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>17</td>
<td></td>
<td>128</td>
<td>128</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>19</td>
<td></td>
<td>128</td>
<td>64</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>64</td>
<td>64</td>
</tr>
<tr>
<td>21</td>
<td></td>
<td>&lt;8</td>
<td>&lt;8</td>
</tr>
</tbody>
</table>

* Sample collected before abortion
† Sample collected at follow up

**Discussion**

The existence of pathogenic micro-organisms in the cervix before therapeutic abortion is of importance, particularly because of the risk of ascending infection. The incidence of chlamyidal infection of the cervix in women undergoing termination of pregnancy is between 6% and 13%.9 In the present study *C. trachomatis* was isolated in 13·8% and *N. gonorrhoeae* in 2-8% of patients.

Most chlamydial infections are confined to the epithelial cells of the mucous membranes of the genital tract. The antigenic stimulus is minimal and the humoral antibody response poor. The use of a sensitive serodiagnostic test is, therefore, important. In the present study an ELISA, which has the same sensitivity and specificity as the single-antigen immunofluorescence test,4 8 was used to detect chlamydial IgG antibodies. Of the 21 patients harboring *C. trachomatis* who were followed up, 17 (81%) had detectable chlamydial IgG antibodies; of these, eight had an appreciable rise in antibody titre. All the six patients who were followed up and developed salpingitis after termination of pregnancy had chlamydial antibodies. These results agree with those obtained by the micro-immunofluorescence test.10 11

The study indicates that patients harbouring *C. trachomatis* in the cervix at termination of pregnancy are at high risk of developing postoperative infections and that *C. trachomatis* is a major aetiological agent in salpingitis occurring after legal abortion. Routine screening for *C. trachomatis* in the cervix before surgery is thus essential. Although only the chlamydia-positive patients were followed up in this study, all patients will be examined thoroughly before and after therapeutic abortion in future studies.

**References**

Therapeutic abortion and Chlamydia trachomatis infection.

E Qvigstad, K Skaug, F Jerve, I S Vik and J C Ulstrup

*Br J Vener Dis* 1982 58: 182-183
doi: 10.1136/sti.58.3.182

Updated information and services can be found at:
http://sti.bmj.com/content/58/3/182

*Email alerting service*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

*Notes*

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/